Top Markets
Coin of the day
Response Genetics, Inc Response Genetics, Inc

Response Genetics, Inc

RGDXQ
株式のランク #42156
Response Genetics, Inc., a life sciences company founded in Los Angeles,... Response Genetics, Inc., a life sciences company founded in Los Angeles, California, in 1999 (originally Bio Type, Inc., before its rebranding in August 2000), focuses on creating, advancing, and commercializing pharmacogenomic tests. These diagnostic tools are crucial for informing cancer treatment decisions by assessing specific indicators within tumor tissue samples that predict a patient's response to therapy. The company provides an extensive array of testing services, primarily through its ResponseDX suite, covering various cancers such as non-small cell lung, colorectal, gastric, gastroesophageal, melanoma, thyroid, breast, and glioma, in addition to a Tissue of Origin test. Beyond these existing solutions, Response Genetics is committed to expanding its diagnostic offerings to encompass other tumor types, while also delivering both the technical execution and professional interpretation components of its testing services. Operating globally, with a significant presence in the United States and Europe, Response Genetics serves a wide range of clients including community oncologists, pathologists, medical practices, hospitals, and pharmaceutical enterprises, primarily through its internal sales force.
株価
$0.0001
最終同期: 2026-08-11
時価総額
$3.87K
変化(1日)
0.00%
変化(1年)
0.00%
US
取引 Response Genetics, Inc (RGDXQ)

カテゴリー

Response Genetics, Inc(RGDXQ)の営業利益率
2026 時点の営業利益率 TTM: 0.00%
Response Genetics, Inc の最新の財務報告と株価によると、現在の営業利益率(TTM)は 0.00% です。2026 年末時点では 0.00% でした。
Response Genetics, Inc の営業利益率の履歴(2026 から 2026)
各年末の営業利益率
営業利益率 変化
提供された日付のデータは十分ではありません。
同業他社の営業利益率
企業 営業利益率 営業利益率の差
17.69% -
US
20.42% -
US
0.00% -
CN
31.63% -
US
-12.97% -
US
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。